SEARCH

SEARCH BY CITATION

References

  • 1
    Anonymous 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785795.
  • 2
    Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW 1999 Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 10:330336.
  • 3
    Simon JA 2004 ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obstet Gynecol 103:203216.
  • 4
    Riggs BL, Melton LJ III 1992 The prevention and treatment of osteoporosis. N Engl J Med 327:620627.
  • 5
    Barrett-Connor E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer M, Cox DA, Moscarelli E, Anderson PW 1998 Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene. J Womens Health 7:839847.
  • 6
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550555.
  • 7
    Lufkin EG, Riggs BL 1996 Three-year follow-up on effects of transdermal estrogen. Ann Intern Med 125:77.
  • 8
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321333.
  • 9
    Reeve J, Bradbeer JN, Arlot M, Davies UM, Green JR, Hampton L, Edouard C, Hesp R, Hulme P, Ashby JP 1991 hPTH 1–34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses. Osteoporos Int 1:162170.
  • 10
    Hodsman AB, Steer BM 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14:523527.
  • 11
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550555.
  • 12
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res 15:944951.
  • 13
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:18461853.
  • 14
    Eriksen EF, Paschalis E, Dobnig H, Ste-Marie LG, Gallagher JC, Donley D, Ma YL 2003 Effects of teriparatide on bone matrix properties and width of remodeling and remodeling osteons at the trabecular and endosteal envelopes. Osteoporos Int Suppl 14:S12.
  • 15
    Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL 2003 Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539543.
  • 16
    Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690709.
  • 17
    Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925931.
  • 18
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:14341441.
  • 19
    Jilka RL 1998 Cytokines, bone remodeling, and estrogen deficiency: A 1998 update. Bone 23:7581.
  • 20
    Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690709.
  • 21
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312321.
  • 22
    Lu Y, Ye K, Mathur AK, Hui S, Fuerst TP, Genant HK 1997 Comparative calibration without a gold standard. Stat Med 16:18891905.
  • 23
    Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925931.
  • 24
    Roe EB, Sanchez SD, del Puerto GA, Pierini E, Bacchetti P, Cann CE, Arnaud CD 1999 Parathyroid hormone 1–34 (hPTH 1–34) and estrogen producedramatic bone density increases in postmenopausal osteoporosis. Results from a placebo-controlled randomized trial. J Bone Miner Res 14S1:S137.
  • 25
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB 2002 A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:45284535.
  • 26
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH 2005 Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:15071513.
  • 27
    Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH 2004 Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623629.
  • 28
    Finkelstein JS, Arnold AL 1999 Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab 84:12141219.
  • 29
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:19321941.
  • 30
    Boyce RW, Paddock CL, Franks AF, Jankowsky ML, Eriksen EF 1996 Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 11:600613.
  • 31
    Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603610.
  • 32
    Ettinger B, San Martin J, Crans GG, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745751.
    Direct Link: